questionsmedicales.fr
Actions chimiques et utilisations
Actions pharmacologiques
Effets physiologiques des médicaments
Agents neuromédiateurs
Agents cholinergiques
Inhibiteurs de la libération d'acétylcholine
Inhibiteurs de la libération d'acétylcholine : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la libération d'acétylcholine : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de la libération d'acétylcholine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de la libération d'acétylcholine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-06",
"dateModified": "2025-05-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la libération d'acétylcholine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Agents cholinergiques",
"url": "https://questionsmedicales.fr/mesh/D018678",
"about": {
"@type": "MedicalCondition",
"name": "Agents cholinergiques",
"code": {
"@type": "MedicalCode",
"code": "D018678",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.696.577.120"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la libération d'acétylcholine",
"alternateName": "Acetylcholine Release Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D065087",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ikunobu Muramatsu",
"url": "https://questionsmedicales.fr/author/Ikunobu%20Muramatsu",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan."
}
},
{
"@type": "Person",
"name": "Junsuke Uwada",
"url": "https://questionsmedicales.fr/author/Junsuke%20Uwada",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan."
}
},
{
"@type": "Person",
"name": "Kiyonao Sada",
"url": "https://questionsmedicales.fr/author/Kiyonao%20Sada",
"affiliation": {
"@type": "Organization",
"name": "Division of Genomic Science and Microbiology, School of Medicine, University of Fukui, Eiheiji, Fukui, Japan."
}
},
{
"@type": "Person",
"name": "Takayoshi Masuoka",
"url": "https://questionsmedicales.fr/author/Takayoshi%20Masuoka",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, School of Medicine, Kanazawa Medical University, Uchinada, Ishikawa, Japan."
}
},
{
"@type": "Person",
"name": "Takashi Yazawa",
"url": "https://questionsmedicales.fr/author/Takashi%20Yazawa",
"affiliation": {
"@type": "Organization",
"name": "Division of Cellular Signal Transduction, Department of Biochemistry, Asahikawa Medical University, Asahikawa, Hokkaido, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Correlation of the regenerative potential of dermal fibroblasts in 2D culture with the biological properties of fibroblast-derived tissue spheroids.",
"datePublished": "2022-09-21",
"url": "https://questionsmedicales.fr/article/36129531",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00441-022-03690-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oral Squamous Cell Carcinoma-Derived ANGPTL3 Induces Cancer Associated Fibroblastic Phenotypes in Surrounding Fibroblasts.",
"datePublished": "2022-12-01",
"url": "https://questionsmedicales.fr/article/36580015",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.31557/APJCP.2022.23.12.4315"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cellular reprogramming of fibroblasts in heart regeneration.",
"datePublished": "2023-03-23",
"url": "https://questionsmedicales.fr/article/36965699",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.yjmcc.2023.03.009"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Role of Gingival Fibroblasts in the Pathogenesis of Periodontitis.",
"datePublished": "2023-03-08",
"url": "https://questionsmedicales.fr/article/36883660",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/00220345231151921"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diversity of Fibroblasts and Their Roles in Wound Healing.",
"datePublished": "2023-03-01",
"url": "https://questionsmedicales.fr/article/36167647",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1101/cshperspect.a041222"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Effets physiologiques des médicaments",
"item": "https://questionsmedicales.fr/mesh/D045505"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents neuromédiateurs",
"item": "https://questionsmedicales.fr/mesh/D018377"
},
{
"@type": "ListItem",
"position": 6,
"name": "Agents cholinergiques",
"item": "https://questionsmedicales.fr/mesh/D018678"
},
{
"@type": "ListItem",
"position": 7,
"name": "Inhibiteurs de la libération d'acétylcholine",
"item": "https://questionsmedicales.fr/mesh/D065087"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de la libération d'acétylcholine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la libération d'acétylcholine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de la libération d'acétylcholine",
"description": "Comment diagnostiquer une inhibition de l'acétylcholine ?\nQuels tests sont utilisés pour évaluer l'acétylcholine ?\nQuels symptômes indiquent une inhibition d'acétylcholine ?\nLes antécédents médicaux sont-ils importants ?\nPeut-on utiliser l'imagerie pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Fibroblasts&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de la libération d'acétylcholine",
"description": "Quels sont les symptômes courants d'une inhibition ?\nL'inhibition affecte-t-elle la cognition ?\nY a-t-il des symptômes respiratoires associés ?\nLes symptômes varient-ils selon l'âge ?\nPeut-on avoir des symptômes digestifs ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Fibroblasts&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de la libération d'acétylcholine",
"description": "Peut-on prévenir l'inhibition d'acétylcholine ?\nL'alimentation joue-t-elle un rôle ?\nL'exercice physique est-il bénéfique ?\nLe stress peut-il aggraver l'inhibition ?\nDes contrôles réguliers sont-ils nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Fibroblasts&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de la libération d'acétylcholine",
"description": "Quels traitements sont disponibles pour l'inhibition ?\nLes traitements sont-ils efficaces ?\nY a-t-il des effets secondaires aux traitements ?\nLa rééducation est-elle recommandée ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Fibroblasts&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de la libération d'acétylcholine",
"description": "Quelles complications peuvent survenir ?\nL'inhibition peut-elle entraîner des hospitalisations ?\nY a-t-il un risque de décès ?\nLes complications sont-elles réversibles ?\nComment gérer les complications ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Fibroblasts&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de la libération d'acétylcholine",
"description": "Quels sont les facteurs de risque d'inhibition ?\nL'âge est-il un facteur de risque ?\nLes médicaments peuvent-ils influencer le risque ?\nLe mode de vie affecte-t-il le risque ?\nLes infections virales sont-elles un risque ?",
"url": "https://questionsmedicales.fr/mesh/D065087?mesh_terms=Fibroblasts&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inhibition de l'acétylcholine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests neurologiques et l'évaluation des symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'acétylcholine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests électromyographiques et des analyses sanguines peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une inhibition d'acétylcholine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la faiblesse musculaire et la fatigue peuvent indiquer une inhibition."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux sont-ils importants ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents médicaux aident à identifier des causes potentielles d'inhibition."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie cérébrale peut aider à exclure d'autres pathologies neurologiques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants d'une inhibition ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent faiblesse musculaire, fatigue, et troubles de la coordination."
}
},
{
"@type": "Question",
"name": "L'inhibition affecte-t-elle la cognition ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des troubles de la mémoire et de la concentration."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes respiratoires associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des difficultés respiratoires peuvent survenir en cas d'inhibition sévère."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent être plus prononcés chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes digestifs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des nausées et des troubles gastro-intestinaux peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'inhibition d'acétylcholine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures préventives incluent un mode de vie sain et la gestion du stress."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée riche en antioxydants peut soutenir la santé neuronale."
}
},
{
"@type": "Question",
"name": "L'exercice physique est-il bénéfique ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la fonction musculaire et nerveuse."
}
},
{
"@type": "Question",
"name": "Le stress peut-il aggraver l'inhibition ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut exacerber les symptômes d'inhibition d'acétylcholine."
}
},
{
"@type": "Question",
"name": "Des contrôles réguliers sont-ils nécessaires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers permettent de surveiller l'évolution et d'ajuster les traitements."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'inhibition ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments anticholinestérasiques et des thérapies physiques."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent améliorer les symptômes et la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des nausées et des crampes peuvent survenir."
}
},
{
"@type": "Question",
"name": "La rééducation est-elle recommandée ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la rééducation physique peut aider à renforcer les muscles et améliorer la fonction."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles respiratoires et des crises musculaires."
}
},
{
"@type": "Question",
"name": "L'inhibition peut-elle entraîner des hospitalisations ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des cas graves peuvent nécessiter une hospitalisation pour surveillance."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de décès ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans des cas extrêmes, l'inhibition sévère peut entraîner des risques mortels."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'inhibition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des maladies auto-immunes, des infections et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge avancé est un facteur de risque pour les troubles de la libération d'acétylcholine."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils influencer le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent augmenter le risque d'inhibition d'acétylcholine."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales peuvent déclencher des troubles de la libération d'acétylcholine."
}
}
]
}
]
}
In situ 3D bioprinting is a new emerging therapeutic modality for treating human skin diseases. The tissue spheroids have been previously suggested as a powerful tool in rapidly expanding bioprinting ...
Angiopoietin-like proteins (ANGPTLs) have emerged as both important regulator of lipid and glucose metabolism as well as insulin sensitivity. In particular, ANGPTL3 activity is one of the most importa...
For our study, we used hTERT-hNOFs to replace CAFs by coculturing them with oral squamous cell carcinoma (OSCC) cells. We did a microarray dataset analysis to investigate what factors secreted from OS...
ANGPTL3 has the most secreted factor derived from various oral cancer cells. To investigate the role of ANGPTL3 in CAFs, we treated rhANGPTL3 in hTERT-hNOFs. The fibroblasts showed an increase of tumo...
In conclusion, our study reports the first evidence that ANGPTL3 plays a crucial role in tumor microenvironments by inducing CAF. Therefore, targeting ANGPTL3 may be promising treatment strategy for C...
Myocardial infarction causes the loss of cardiomyocytes and the formation of cardiac fibrosis due to the activation of cardiac fibroblasts, leading to cardiac dysfunction and heart failure. Unfortunat...
Gingival fibroblasts (GFs) are essential components of the periodontium, which are responsible for the maintenance of tissue structure and integrity. However, the physiological role of GFs is not rest...
Wound healing disorders are a societal, clinical, and healthcare burden and understanding and treating them is a major challenge. A particularly important cell type in the wound healing processes is t...
The role of different G protein-coupled receptors (GPCRs) in the cardiovascular system is well understood in cardiomyocytes and vascular smooth muscle cells (VSMCs). In the former, stimulation of Gs-c...
Injuries to our skin trigger a cascade of spatially- and temporally-synchronized healing processes. During such endogenous wound repair, the role of fibroblasts is multifaceted, ranging from the activ...
Cardiovascular disease is the leading cause of death worldwide, outpacing pulmonary disease, infectious disease, and all forms of cancer. Myocardial infarction (MI) dominates cardiovascular disease, c...
Periodontal diseases include periodontitis and gingival overgrowth. Periodontitis is a bacterial infectious disease, and its pathological cascade is regulated by many inflammatory cytokines secreted b...
The extracellular matrix serves as a scaffold for cardiomyocytes, allowing them to work in accord. In rats, collagen metabolism within a myocardial infarction scar is regulated by melatonin. The prese...
The experiments were performed on cultures of cardiac fibroblasts. The Woessner method, 1,9-dimethylmethylene blue assay, enzyme-linked immunosorbent assay and quantitative PCR were used in the study....
Melatonin treatment lowered the total cell count within the culture, elevated necrotic and apoptotic cell count as well as augmented cardiac fibroblast proliferation, and increased total, intracellula...
Within human cardiac fibroblast culture, collagen metabolism is regulated by melatonin. The profibrotic effect of melatonin depends on the elevation of procollagen type III gene expression, and this c...